Among 428 GGO pathological samples with pathologically confirmed adenocarcinoma, 262 (61.2%) GGO lesions had EGFR gene mutations, including 112 exon 19 deletions, 136 L858R missense mutations, 4 20INS insertion mutations, 3 G719X mutation and 3 L861Q mutations. This evidence concerns the gene EGFR and adenocarcinoma.